Slocum Gordon & Co LLP Has $5.56 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Slocum Gordon & Co LLP lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 260,229 shares of the company’s stock after selling 6,046 shares during the quarter. Kenvue comprises approximately 4.6% of Slocum Gordon & Co LLP’s investment portfolio, making the stock its 7th biggest position. Slocum Gordon & Co LLP’s holdings in Kenvue were worth $5,556,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Huntington National Bank boosted its position in shares of Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after acquiring an additional 871 shares in the last quarter. ING Groep NV raised its holdings in shares of Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock worth $82,727,000 after buying an additional 681,954 shares in the last quarter. Everence Capital Management Inc. lifted its position in shares of Kenvue by 122.1% during the 4th quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock worth $969,000 after buying an additional 24,950 shares during the last quarter. Saturna Capital Corp boosted its stake in Kenvue by 29.9% in the third quarter. Saturna Capital Corp now owns 1,334,860 shares of the company’s stock valued at $30,875,000 after buying an additional 307,039 shares in the last quarter. Finally, Tyler Stone Wealth Management grew its position in Kenvue by 134.4% in the third quarter. Tyler Stone Wealth Management now owns 49,050 shares of the company’s stock valued at $1,135,000 after acquiring an additional 28,125 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE opened at $19.78 on Friday. The business has a 50-day moving average of $21.70 and a 200-day moving average of $21.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $37.93 billion, a price-to-earnings ratio of 35.97, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 4.15%. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on KVUE shares. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday. Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. UBS Group cut their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a report on Thursday, January 16th. Finally, Citigroup lowered their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.